NCT00264615View on ClinicalTrials.gov

Patients With Epilepsy Taking LAMICTAL Immediate-Release Who Switch To Extended-Release Formulation And Vice Versa

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

June 30, 2006

Study Completion Date

June 30, 2006

Conditions
Epilepsy
Interventions
DRUG

lamotrigine extended-release

Trial Locations (12)

10016

GSK Investigational Site, New York

19140

GSK Investigational Site, Philadelphia

23219

GSK Investigational Site, Richmond

36207

GSK Investigational Site, Anniston

37232

GSK Investigational Site, Nashville

40503

GSK Investigational Site, Lexington

75230

GSK Investigational Site, Dallas

85351

GSK Investigational Site, Sun City

89521

GSK Investigational Site, Reno

40536-0284

GSK Investigational Site, Lexington

02215

GSK Investigational Site, Boston

43614-5809

GSK Investigational Site, Toledo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY